|
 |
|
|||||||
|
|||||||||
Diabetes 52:536-541, 2003
© 2003 by the American Diabetes Association, Inc.
Amelioration of Sensory Nerve Dysfunction by C-Peptide in Patients With Type 1 Diabetes
1 Department of Surgical Sciences, Section of Clinical Physiology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
2 Section of Clinical Neurophysiology, Karolinska Institutet, Stockholm, Sweden
3 Section of Neurology, Karolinska Institutet, Stockholm, Sweden
Studies have demonstrated that proinsulin C-peptide stimulates the activities of Na+,K+-ATPase and endothelial nitric oxide synthase, both of which are enzyme systems of importance for nerve function and known to be deficient in type 1 diabetes. The aim of this randomized double-blind placebo-controlled study was to investigate whether C-peptide replacement improves nerve function in patients with type 1 diabetes. Forty-nine patients without symptoms of peripheral neuropathy were randomized to either 3 months of treatment with C-peptide (600 nmol/24 h, four doses s.c.) or placebo. Forty-six patients (15 women and 31 men, aged 29 years, diabetes duration 10 years, and HbA1c 7.0%) completed the study. Neurological and neurophysiological measurements were performed before and after 6 and 12 weeks of treatment. At baseline the patients showed reduced nerve conduction velocities in the sural nerve (sensory nerve conduction velocity [SCV]: 50.9 ± 0.70 vs. 54.2 ± 1.2 m/s, P < 0.05) and peroneal nerve (motor nerve conduction velocity: 45.7 ± 0.55 vs. 53.5 ± 1.1 m/s, P < 0.001) compared with age-, height-, and sex-matched control subjects. In the C-peptide treated group there was a significant improvement in SCV amounting to 2.7 ± 0.85 m/s (P < 0.05 compared with placebo) after 3 months of treatment, representing 80% correction of the initial reduction in SCV. The change in SCV was accompanied by an improvement in vibration perception in the patients receiving C-peptide (P < 0.05 compared with placebo), whereas no significant change was detectable in cold or heat perception. In conclusion, C-peptide administered for 3 months as replacement therapy to patients with early signs of diabetic neuropathy ameliorates nerve dysfunction.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Del Carro, P. Fiorina, S. Amadio, L. De Toni Franceschini, A. Petrelli, S. Menini, F. M. Boneschi, S. Ferrari, G. Pugliese, P. Maffi, et al. Evaluation of Polyneuropathy Markers in Type 1 Diabetic Kidney Transplant Patients and Effects of Islet Transplantation: Neurophysiological and skin biopsy longitudinal analysis Diabetes Care, December 1, 2007; 30(12): 3063 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ekberg, T. Brismar, B.-L. Johansson, P. Lindstrom, L. Juntti-Berggren, A. Norrby, C. Berne, H. J. Arnqvist, J. Bolinder, and J. Wahren C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy Diabetes Care, January 1, 2007; 30(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kamiya, W. Zhang, K. Ekberg, J. Wahren, and A. A.F. Sima C-Peptide Reverses Nociceptive Neuropathy in Type 1 Diabetes Diabetes, December 1, 2006; 55(12): 3581 - 3587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Al-Rasheed, G. B. Willars, and N. J. Brunskill C-Peptide Signals via G{alpha}i to Protect against TNF-{alpha}-Mediated Apoptosis of Opossum Kidney Proximal Tubular Cells J. Am. Soc. Nephrol., April 1, 2006; 17(4): 986 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.M. Boulton, A. I. Vinik, J. C. Arezzo, V. Bril, E. L. Feldman, R. Freeman, R. A. Malik, R. E. Maser, J. M. Sosenko, and D. Ziegler Diabetic Neuropathies: A statement by the American Diabetes Association Diabetes Care, April 1, 2005; 28(4): 956 - 962. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maestroni, D. Ruggieri, G. Dell'Antonio, L. Luzi, and G. Zerbini C-peptide increases the expression of vasopressin-activated calcium-mobilizing receptor gene through a G protein-dependent pathway Eur. J. Endocrinol., January 1, 2005; 152(1): 135 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ziegler Polyneuropathy in the diabetic patient--update on pathogenesis and management Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2170 - 2175. [Full Text] [PDF]
|
|
|
|
|
|
B. Samnegard, S. H. Jacobson, B.-L. Johansson, K. Ekberg, B. Isaksson, J. Wahren, and M. Sjoquist C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1385 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]
|
|
|
|
|
|
A. A.F. Sima, W. Zhang, Z.-G. Li, Y. Murakawa, and C. R. Pierson Molecular Alterations Underlie Nodal and Paranodal Degeneration in Type 1 Diabetic Neuropathy and Are Prevented by C-Peptide Diabetes, June 1, 2004; 53(6): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-L. Johansson, J. Wahren, and J. Pernow C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E864 - E870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cotter, K. Ekberg, J. Wahren, and N. E. Cameron Effects of Proinsulin C-Peptide in Experimental Diabetic Neuropathy: Vascular Actions and Modulation by Nitric Oxide Synthase Inhibition Diabetes, July 1, 2003; 52(7): 1812 - 1817. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |